ADDPI 2022_253 INADA vs Vinit

In July 2022 the India National Anti-Doping Agency (INADA) has reported an anti-doping rule violation against the Athlete Vinit after his sample tested positive for the prohibited substance Metandienone.

Following notification a provisional suspension was ordered. The Athlete filed a statement in his defence and he was heard for the Anti-Doping Disciplinary Panel of India (ADDPI).

The Athlete denied the intentional use of the substance and assumed that a contaminated supplement was the source of the positive test result. However analysis of his supplements in the New Delhi Laboratory did not reveal any prohibited substances.

The Athlete did not accept the test report from the New Delhi Laboratory and produced a test report from another laboratory showing the presence of contaminants in his supplements.

The Panel finds that the presence of a prohibited substance has been established in the Athlete's sample and accordingly that he committed an anti-doping rule violation.

Regarding the Athlete's supplements the Panel considered only the test report from the New Delhi Laboratory and not the Athlete's alternative test report. The Panel deems that the Athlete failed to demonstrate that the violation was not intentional, nor that he had acted carefully with his supplements.

Therefore the Panel decides on 3 April 2023 to impose a 4 year period of ineligibility on the Athlete, starting on the date of the provisional suspension, i.e. on 7 July 2022.

Original document

Parameters

Legal Source
National Decisions
Date
3 April 2023
Arbitrator
Arya, Rajendra Kumar
Deka, Abantika
Pragya, Charu
Original Source
India National Anti-Doping Agency (INADA)
Country
India
Language
English
ADRV
Adverse Analytical Finding / presence
Sport/IFs
Athletics (WA) - World Athletics
Other organisations
Anti-Doping Disciplinary Panel of India (ADDPI)
India National Anti-Doping Agency (INADA)
Laboratories
New Delhi, India: National Dope Testing Laboratory
Doping classes
S1. Anabolic Agents
Substances
Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one)
Various
Supplements
Document type
Pdf file
Date generated
1 May 2023
Date of last modification
22 May 2023
Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin